Perrigo Company plc Available-for-sale Securities, Gross Realized Gains
Perrigo Company plc (PRGO) reported Available-for-sale Securities, Gross Realized Gains of $1.60 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGains · last filed 2018-03-01
- Perrigo Company plc available-for-sale securities, gross realized gains for the quarter ending 2017-12-31 was $0.00.
- Perrigo Company plc available-for-sale securities, gross realized gains for the quarter ending 2017-09-30 was $0.00.
- Perrigo Company plc available-for-sale securities, gross realized gains for the quarter ending 2017-07-01 was $0.00.
- Perrigo Company plc available-for-sale securities, gross realized gains for the quarter ending 2017-04-01 was $1.60M.
- Perrigo Company plc available-for-sale securities, gross realized gains for fiscal 2017 was $1.60M, a 60.00% increase from fiscal 2016.
- Perrigo Company plc available-for-sale securities, gross realized gains for fiscal 2016 was $1.00M.
| Period end | Available-for-sale Securities, Gross Realized Gains 3 month | Available-for-sale Securities, Gross Realized Gains 6 month | Available-for-sale Securities, Gross Realized Gains 9 month | Available-for-sale Securities, Gross Realized Gains 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | $0.00 derived: sum of 3 quarters · filed 2018-03-01 | $1.60M 10-K · filed 2018-03-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $1.60M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $1.60M 10-Q · filed 2017-08-10 | ||
| 2017-04-01 | $1.60M 10-Q · filed 2017-05-30 | |||
| 2016-12-31 | $1.00M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |